CORRECTION

Correction to: Optimising the Benefits of SGLT2 Inhibitors for Type 1 Diabetes

Marc Evans · Debbie Hicks · Dipesh Patel · Vinod Patel ·
Phil McEwan · Umesh Dashora

Published online: December 31, 2019
© The Author(s) 2019

Correction to: Diabetes Ther

<https://doi.org/10.1007/s13300-019-00728-6>

In the original article, Associated Medical Education Section has been published mistakenly. It has been removed from the original publication.

The original version of this article was revised.

Open Access. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

The original article can be found online at <https://doi.org/10.1007/s13300-019-00728-6>.

M. Evans (✉)
Diabetes Resource Centre, University Hospital
Llandough, Cardiff, UK
e-mail: marclyndon1@hotmail.com

D. Hicks
Medicus Health Partners, Enfield, London, UK

D. Patel
Department of Diabetes, Division of Medicine,
University College London, Royal Free NHS Trust,
London, UK

V. Patel
Warwick Medical School, University of Warwick,
George Eliot Hospital NHS Trust, Nuneaton, UK

P. McEwan
Health Economics and Outcomes Research Ltd.,
Cardiff, UK

U. Dashora
East Sussex Healthcare NHS Trust, Eastbourne, UK